Enanta Pharmaceuticals | ENTA - Current Liabilities


Enanta Pharmaceuticals reported $44.73M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Anika Therapeutics USD 21.91M 2.82M Dec/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Immunic USD 30.08M 2.77M Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
J&J USD 54.13B 3.26B Dec/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Ligand Pharmaceuticals USD 37.45M 6.91M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Novavax USD 459.95M 30.08M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025